Jiangsu Hengrui Pharmaceuticals Co has a current ratio of 9.23. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
SHSE:600276'
s Current Ratio Range Over the Past 10 Years
Min: 6.52 Med: 8.53 Max: 13.49
Current: 9.23
During the past 13 years, Jiangsu Hengrui Pharmaceuticals Co's highest Current Ratio was 13.49. The lowest was 6.52. And the median was 8.53.
SHSE:600276's Current Ratio is ranked better than 93.68% of 997
companies
in the Drug Manufacturers industry
Industry Median: 2
vs SHSE:600276: 9.23
Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Jiangsu Hengrui Pharmaceuticals Co Current Ratio Related Terms
Jiangsu Hengrui Pharmaceuticals Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Hengrui Pharmaceuticals Co Current Ratio Chart
SHSE:600276 vs ZTS, UTHR: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Hengrui Pharmaceuticals Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Hengrui Pharmaceuticals Co Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) has a Current Ratio of 9.23 as of Mar. 2026. This is near median its historical median of 8.53. Over the past decade, Jiangsu Hengrui Pharmaceuticals Co's Current Ratio has ranged from 6.52 to 13.49. According to the industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #63 out of 997 companies in the Drug Manufacturers industry, placing it in the top 6.3%.
Is Jiangsu Hengrui Pharmaceuticals Co's Current Ratio too high?
Jiangsu Hengrui Pharmaceuticals Co's current Current Ratio of 9.23 is near median its 10-year median of 8.53. Over the past 10 years, this metric has ranged from a low of 6.52 to a high of 13.49. The Drug Manufacturers industry median Current Ratio is 2.00. Jiangsu Hengrui Pharmaceuticals Co's value of 9.23 is 361.5% above this industry median. Based on the distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #63 out of 997 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jiangsu Hengrui Pharmaceuticals Co has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hengrui Pharmaceuticals Co's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #63 out of 997 companies for Current Ratio. This places Jiangsu Hengrui Pharmaceuticals Co in the top 6% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.00. Jiangsu Hengrui Pharmaceuticals Co's value of 9.23 is 361.5% above this benchmark. Historically, Jiangsu Hengrui Pharmaceuticals Co's own Current Ratio has ranged from 6.52 to 13.49 over the past decade. While the company's 10-year median is 8.53 vs. the industry median of 2.00, Jiangsu Hengrui Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Hengrui Pharmaceuticals Co's current Current Ratio of 9.23 is 361.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Hengrui Pharmaceuticals Co's current Current Ratio is 9.23, which is near median its own 10-year median of 8.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hengrui Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) is currently considered Fairly Valued. The stock's GF Value™ is ¥60.61, compared to a current price of ¥55.65 — trading 8.2% below its estimated fair value. The current Current Ratio is 9.23, which is near median its 10-year median of 8.53 and 361.5% above the Drug Manufacturers industry median of 2.00. Jiangsu Hengrui Pharmaceuticals Co's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276), the current Current Ratio is 9.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥55.65 is trading 8.2% below its estimated GF Value™ of ¥60.61.
GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Fairly Valued.
Key valuation signals for SHSE:600276:
Current Ratio: 9.23 (near median its 10-year median of 8.53)
GF Value™: ¥60.61 vs. price of ¥55.65 (8.2% below fair value)
Industry Position: 361.5% above the Drug Manufacturers median (#63 of 997)
No single metric tells the full story. See the SHSE:600276 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Hengrui Pharmaceuticals Co Business Description
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
86GF Score
Get the complete analysis for SHSE:600276
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600276 has been successfully added to your 
